Cancer models have showed that increased expression of IL-6 enhances acquired cisplatin resistance and reduces cytotoxicity; therefore, direct stimulation of IL-6 over-expression may reduce the efficacy of cisplatin [282] and therefore may not be an appropriate therapeutic target for cancer patients to prevent CIAKI. The gene discussed is IL6; the disease is cancer.